Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | 2026 / For the Three Months Ended / March 31, | 2025 / For the Three Months Ended / March 31, |
|---|---|---|
| Net loss | $(10,086,687) | $(4,542,528) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 575,565 | 868,359 |
| Depreciation | 91,577 | 38,153 |
| Amortization of right of use asset | 39,189 | 21,027 |
| Loss on disposal of fixed assets | 34,153 | - |
| Realized gain on available-for-sale securities | (10,648) | - |
| Changes in operating assets and liabilities: |
Document
FAQ
- What is Immix Biopharma, Inc.'s D&A?
- Immix Biopharma, Inc. (IMMX) reported D&A of $91.58K in Q1 2026.
- How has Immix Biopharma, Inc.'s D&A changed year-over-year?
- Immix Biopharma, Inc.'s D&A increased by 140.0% year-over-year, from $38.15K to $91.58K.
- What is the long-term trend for Immix Biopharma, Inc.'s D&A?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s D&A has grown at a 215.9% compound annual growth rate (CAGR), from $2.47K to $245.75K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Immix Biopharma, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude